Annual report pursuant to Section 13 and 15(d)

License Agreement (Details Textual)

v3.19.1
License Agreement (Details Textual) - USD ($)
$ in Millions
1 Months Ended
Oct. 29, 2018
Jun. 17, 2015
Revogenex License [Member]    
Contractual Obligation, Maximum Future Payments   $ 4.0
IV Tramadol [Member] | Fortress Biotech, Inc [Member]    
Payments to Acquire in Process Research and Development   3.0
IV Tramadol [Member] | Fortress Biotech, Inc [Member] | Upfront Payment [Member]    
Payments to Acquire in Process Research and Development   2.0
IV Tramadol [Member] | Fortress Biotech, Inc [Member] | Additional Payment [Member]    
Payments to Acquire in Process Research and Development   $ 1.0
Polharma [Member]    
Payments to Acquire in Process Research and Development $ 2.0